The Scripps Research Institute Enters Major Five-Year $100 Million Collaboration with Pfizer
They will jointly study and evaluate therapeutic approaches for diseases such as cancer, diabetes, and mental illnesses. They will develop new tests to rapidly validate these new therapies for potential development as possible novel treatment options that can gain regulatory approval for use in patients.
The company will pay the Institute milestones and royalties on therapeutic compounds created through the collaboration. In addition, Pfizer will have the first right to license many discoveries made at Scripps Research during the agreement.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.